Journal of the Korean Medical Association (대한의사협회지)

Korean Medical Association (대한의사협회)
권호 표지
DOI QR코드

DOI QR Code

Pharmacological treatment for reflux esophagitis

역류성 식도염의 약물치료

  • Jung, Hwoon-Yong (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine)
  • 정훈용 (울산대학교 의과대학 서울아산병원 소화기내과)
  • Published : 2011.01.10
⟨ Previous Next ⟩

Abstract

Proton pump inhibitors (PPIs) can ameliorate reflux symptoms and heal esophageal injury by rapid inhibition of acid secretion. PPIs are used as an initial treatment as well as for maintenance purposes. Eight weeks are necessary for complete healing of esophageal injury. After initial therapy, symptomatic recurrence rates are as high as 85% within one year. Therefore, to maintain a good quality of life, many patients need half or usual dose of a PPI for maintenance. There are three kinds of maintenance therapy including continuous, intermittent, and on-demand therapy. PPIs are very safe to use. Adverse events including headache, skin rashes, diarrhea, and weakness have a very low prevalence. Longstanding use of a PPI, however, may be associated with several medical problems such as community-acquired infection and osteoporosis because of a chronic intragastric hypochlorhydric state. PPIs are definitely superior to H2-receptor antagonists and other medications in terms of their treatment potency and safety.

Keywords

References

  1. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010;139:1115-1127. https://doi.org/10.1053/j.gastro.2010.08.023
  2. van Boxel OS, van Oijen MG, Hagenaars MP, Smout AJ, Siersema PD. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010;105:2430-2436. https://doi.org/10.1038/ajg.2010.334
  3. Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, Lacreta FP, Hurbin F, Dubar M. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011;89:65-74. https://doi.org/10.1038/clpt.2010.219
  4. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909- 1917. https://doi.org/10.1056/NEJMoa1007964
  5. Wu CY, Chan FK, Wu MS, Kuo KN, Wang CB, Tsao CR, Lin JT. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology 2010;139:1165-1171. https://doi.org/10.1053/j.gastro.2010.06.067

Cited by

  1. 대황 감초 복합추출물의 항산화 효과를 통한 역류성 식도염 개선 효과 vol.30, pp.4, 2011, https://doi.org/10.6116/kjh.2015.30.4.37.